High-dose intravenuos IgG (hdIVIg) and bosentan therapy in severe scleromyxedema with pulmonary fibrosis:another chance

MLA

Lagana’, Bruno, et al. High-Dose Intravenuos IgG (HdIVIg) and Bosentan Therapy in Severe Scleromyxedema with Pulmonary Fibrosis:Another Chance. Jan. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3686..b8896e88de4d8fadcf325836a469709d&authtype=sso&custid=ns315887.

APA

Lagana’, B., Luzi, G., Di Rosa, R., Salemi, S., Germano, V., Picchianti Diamanti, A., Podestà, E., Sorgi, M. L., & D’Amelio, R. (2009). High-dose intravenuos IgG (hdIVIg) and bosentan therapy in severe scleromyxedema with pulmonary fibrosis:another chance.

Chicago

Lagana’, Bruno, G. Luzi, Roberta Di Rosa, S. Salemi, V. Germano, A. Picchianti Diamanti, E. Podestà, Maria Laura Sorgi, and R. D’Amelio. 2009. “High-Dose Intravenuos IgG (HdIVIg) and Bosentan Therapy in Severe Scleromyxedema with Pulmonary Fibrosis:Another Chance,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3686..b8896e88de4d8fadcf325836a469709d&authtype=sso&custid=ns315887.